Introduction

▼
Antidepressant drugs have been widely prescribed in patients with bipolar disorder, despite clinicians' concern about antidepressant-induced manic switch and the recommendations of practice guidelines. In a recent report on antidepressant use in bipolar disorder, the task force of the International Society of Bipolar Disorders (ISBD) stated that there is striking incongruity between the wide use of antidepressant drugs in bipolar disorder and the weak evidence base for their efficacy and safety. As the frequency and severity of antidepressant-induced manic switch appears to be greater in bipolar I disorder than bipolar II, it is recommended that antidepressants should only be prescribed to bipolar I patients as an adjunct to mood-stabilizing medications [1] . Although the true rate of antidepressant-induced manic switch in bipolar disorder is a controversial issue, there is a consensus that various antidepressants have differing potential for inducing such a switch. Most studies show that such a potential is higher for tricyclic antidepressants (TCAs) and venlafaxine than for selective seroto-of insomnia is much greater than for sedative antipsychotics. Sedative antidepressants may also be better tolerated [9] . Furthermore, the doses of antidepressants needed to promote sleep are much lower than the doses needed to treat depression [6] , so the risk of switching is probably very low. In this article, we review published case reports describing the switch to mania or hypomania during treatment with trazodone, mirtazapine, or agomelatine, both in monotherapy and in combination with mood stabilizers, and used both in the therapeutic doses for antidepressant effect and in the low doses recommended to promote sleep.
Methods
▼
We performed a literature search in PubMed for articles published in the English language, which were published up to September 2014, using the following search terms in the title or abstract: the antidepressant name (trazodone, mirtazapine, agomelatine) AND mania, hypomania, bipolar disorder, or phase shift. To ensure accuracy, the search performed by the first author of this paper was independently repeated by 2 reviewers (M.J., Ł.O.). Furthermore, references of selected papers and relevant review articles were scanned by all authors in order to locate other reports.
Results
▼
Trazodone
Trazodone is an antidepressant of the serotonin antagonist and reuptake inhibitor (SARI) class. Low doses of trazodone (below 150 mg/day) only act via the most potent binding properties, that is, the serotonergic 5HT2A receptors, whereas higher doses recruit additional pharmacological action and result in the blockade of the serotonin transporter (SERT). The ability of trazodone to block SERTs is 100-fold less potent than its ability to block 5HT2A receptors. As both of these actions are considered necessary for an antidepressant effect, the trazodone dose recommended for the treatment of depression is usually above 150 mg/day [10] , whereas low doses (25-150 mg/day) are usually sufficient for sleep-promoting effects [6] . The development of switch to mania or hypomania associated with trazodone treatment was described in 17 patients ( • ▶ Table 1 ).
9 of those patients were treated in monotherapy with the antidepressant dose ( ≥ 150 mg/day) of trazodone [11] [12] [13] [14] [15] [16] [17] [18] . In only 4 cases, monotherapy with a low dose of trazodone (100 mg/day) was found to be associated with switch to mania or hypomania [11, 13, 14] . All of these 4 cases were older patients (over 60 years old), so they could have a slower elimination rate and, therefore, higher trazodone plasma concentrations compared to the younger patients. Furthermore, in 3 of those 4 patients, other factors were present that could increase the risk of switch to mania. 2 patients were treated with other antidepressants before the start of the trazodone treatment, and one patient obtained trazodone treatment during detoxification from benzodiazepines. In only 2 patients, a very low dose of trazodone (50 mg/day) was described as being related to switch to mania or a mixed depressive state. In both cases, treatment with trazodone was combined with other antidepressants, and in one patient additionally with a non-pharmacological intervention (continuous positive airway pressure, CPAP) [19, 20] A nonpharmacological intervention (repetitive transcranial magnetic stimulation, rTMS) added to combined treatment with trazodone (200 mg/day), paroxetine, opipramol, amitriptyline, prazepam and methadone induced a depressive mixed episode in a further patient [21] . In one patient, a switch to hypomania was observed 3 weeks after the discontinuation of trazodone treatment [16] . Additionally, in 2 depressed patients with probable bipolar disorder, who did not respond to trazodone, a switch to mania was described after trazodone was abruptly replaced with imipramine [22] . There are no published cases describing a switch to mania or hypomania in patients who were treated with a mood stabilizer and trazodone as an antidepressant or a sleep-promoting treatment. The average time until the onset of mania/hypomania after the start of treatment with trazodone was 14.7 days (median 7 days). 9 patients were described as switching to mania, 6 to hypomania, one to hypomania followed by a mixed episode, and one to a mixed depressive episode.
Mirtazapine
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Its mechanism of action involves noradrenergic alpha2-auto-and hetero-receptor blockade, enhancing noradrenaline (NE) and serotonin (5-HT) release, as well as blockade of serotonergic 5-HT2 and 5-HT3 and histaminergic H1 receptors [23] . The recommended dose of mirtazapine for the treatment of depression is 30-45 mg/day because, in this dose range, mirtazapine acts as an alpha2 antagonist and a 5-HT and NE disinhibitor. However, for the sleep-promoting effect, only the antagonistic action of mirtazapine on histaminergic H1 receptors is necessary. For this effect, low doses of mirtazapine of 3.75-15 mg/day are usually sufficient [6] . Development of a switch to mania or hypomania associated with mirtazapine treatment was described in 10 patients Table 2 ).
3 of those patients were treated in monotherapy with the antidepressant dose ( ≥ 30 mg/day) of mirtazapine [24] [25] [26] . One of those patients may have been at higher risk of switching, because she was an older patient and the treatment with mirtazapine was started without a period of washout from fluoxetine (20 mg/ day) [26] . In 2 further patients, treatment with antidepressant dose of mirtazapine was combined with treatment using SSRIs [27, 28] . In one patient hypomania was observed after a dose of mirtazapine was increased to 60 mg/day [29] . Mirtazapine doses lower than 30 mg/day were found to be associated with switch to mania or hypomania in only 3 cases [30] [31] [32] . In the first of those patients, mirtazapine (15 mg/day) was added to a high dose (250 mg/day) of sertraline [32] . The second patient was an older patient, a 68-year-old woman with organic, post-stroke depression [30] , and the third patient was a young patient, a 15-year-old girl [31] . In one older depressed patient, a switch to hypomania was observed 2 days after mirtazapine discontinuation, following 35 days of treatment [33] . There are no published cases that describe a switch to mania or hypomania in patients who were treated with a mood stabilizer and mirtazapine either in antidepressant or in a sleep-promoting dose. The average time until the onset of mania/hypomania after the start of the treatment or a dose increase of mirtazapine was 15.7 days (median 7 days). 5 patients were described as switching to mania, 4 to hypomania, and one to a mixed depressive episode.
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Agomelatine
Agomelatine is an antidepressant with a novel non-monoaminergic mechanism of action. It is a melatonin agonist at both melatonin receptors MT1 and MT2 and a serotonin antagonist at 5-HT2C receptors. The recommended dose of agomelatine to treat depression is 25-50 mg/day [34] . So far, it is unknown whether lower doses of agomelatine can be used to have only a sleep-promoting effect. Recently, a switch to hypomania has been described in a 52-yearold female patient with the diagnosis of a recurrent major depressive disorder and comorbid panic disorder. The patient was treated with paroxetine 20 mg/day and trazodone 100 mg/ day. As no improvement was observed after 1 month, the patient was admitted to hospital and the paroxetine treatment was shifted to agomelatine 25 mg/day, while 100 mg/day trazodone was maintained. After 4 days, the symptoms of hypomania occurred, and the agomelatine was discontinued 2 days later. One week after stopping the agomelatine treatment, the hypomanic symptoms remitted [35] . In a study that evaluated the efficacy of agomelatine in patients with bipolar I disorder, who were experiencing a major depressive episode during treatment with lithium or valpromide, there were 3 of 13 agomelatine and lithium treated patients who experienced manic or hypomanic episodes during an optional observation period of up to 46 weeks Only one of those cases was rated as treatment-related [36] .
Discussion
▼
The described cases suggest that trazodone, mirtazapine, and agomelatine may induce manic symptoms in some patients. It happens most frequently at an early stage of treatment, which has been already noticed before [37] . The risk of a switch to mania or hypomania during treatment with trazodone or mirtazapine seems to be related, first of all, to the doses recommended for antidepressant treatment, administered without concomitant mood-stabilizer therapy. Low doses of these antidepressants, which can be used for their hypnotic or sedative effects, were observed to cause a switch to mania or hypomania only in patients with other risk factors for switching, such as treatment with other antidepressants, organic origin of the depressive symptoms, and being of an older or very young age. There is no evidence for trazodone and mirtazapine, and only sparse evidence for agomelatine [36] , claiming that treatment with these antidepressants is related to an increased risk of switch to mania when administered in combination with a mood stabilizer. This last finding of our review is supported by results of a recent study based on Swedish national registries, which examined the risk of antidepressant-induced manic switch in patients with bipolar disorder who were being treated either with antidepressant monotherapy or with an antidepressant in conjunction with a mood stabilizer. Although an increased risk of manic switch was found among patients with bipolar disorder on antidepressant monotherapy, the risk of manic episodes was not increased in the short or long term for patients treated with an antidepressant and a concurrent mood stabilizer [38] .
To interpret the findings from the case reports reviewed by us, we have to take into account that switching to mania or hypomania related to treatment with trazodone, mirtazapine, or agomelatine may be more common, but underreported. The reason may be, for example, the relatively mild intensity of the hypomanic symptoms. In many described case reports, the described symptoms did not require any other action than stopping or reducing the dose of the administered antidepressant. Some authors even claimed that, in their experience, trazodoneinduced hypomanic symptoms may be transient and that immediate withdrawal of trazodone may not always be necessary [13] . In some cases, switching to mania or hypomania may also be considered as resulting from illness progression [39] or stressful life events [40] . However, at least for mirtazapine, the low risk of a switch to mania was also found in studies that analyzed data from clinical trials. In a review of the initial clinical trials, manic symptoms associated with mirtazapine treatment were described in 3 (0.25 %) of 1 299 patients [41] . In a study that analyzed data from 2 clinical trials in patients with rapid-cycling bipolar disorder, the rate of treatment-derived mania/hypomania was 30.1 % for SSRIs (highest for fluoxetine 42.1 %, lowest for fluvoxamine 0 %), 35.7 % for bupropion, 30.6 % for venlafaxine, 18.8 % for nefazodone (a drug with similar pharmacological action to trazodone), and there were no cases of switching observed for mirtazapine [42] . All of these data suggest that low doses of trazodone and mirtazapine are safe in patients with bipolar disorder and should still be considered as important alternatives to hypnotics when long-term pharmacological treatment of insomnia is necessary.
We believe that such a use of sleep-promoting antidepressants can even decrease the risk of switching, because the effective treatment of insomnia in bipolar patients improves the course of the disorder and quality of life. It also seems that trazodone, mirtazapine, and agomelatine can be used safely in antidepressant doses when combined with a mood stabilizer, especially in patients with bipolar II disorder. Further work should clarify whether doxepin, the only sedative antidepressant approved by the FDA for the treatment of insomnia characterized by difficulty with sleep maintenance, can also be used to treat insomnia in bipolar disorder. Although TCAs are regarded as antidepressants with the highest risk of a switch to mania [43] , there is no evidence to claim that low doses (3 and 6 mg) of doxepin, which show only antihistaminergic effects [6, 44] , are related to treatment-emergent mania or hypomania. Another interesting tricyclic antidepressant worthy of consideration as sleep-promoting drug is trimipramine. Trimipramine is regarded as an atypical antidepressant with antipsychotic and sedative properties. It has been studied in monotherapy in delusional depression [45] and in low dose to treat primary insomnia [46] . In some countries it is frequently used to induce sleep, also as adjuvant therapy to other drugs [47] . It is also noteworthy that the sleep-promoting effect may not be the most relevant feature for estimating the switch risk and choice of an antidepressant. In patients with bipolar disorder without sleep problems a dopaminergic antidepressant bupropion may be a reasonable first-line treatment. Bupropion has lower rates of manic switch than tricyclic and tetracyclic antidepressants and norepinephrine-serotonin reuptake inhibitors [1] and is especially useful, e. g., in bipolar disorder comorbid with attention-deficit/hyperactivity disorder [48] .
